|
Category:propellants, aerating agents, and gas
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | colorless gas (est) |
| Assay: | 95.00 to 100.00
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | -131.00 °C. @ 760.00 mm Hg (est)
|
| Boiling Point: | -19.00 °C. @ 760.00 mm Hg (est)
|
| Vapor Pressure: | 3402.334000 mmHg @ 25.00 °C. (est) |
| Vapor Density: | 4.2 at ( Air = 1 ) |
| Flash Point: | -58.00 °F. TCC ( -50.10 °C. ) (est)
|
| logP (o/w): | 1.610 (est) |
| Soluble in: |
| | water, 79.5 mg/L @ 25 °C (est) |
Organoleptic Properties:
| Odor and/or flavor descriptions from others (if found). |
Cosmetic Information:
Suppliers:
Safety Information:
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
|
Not determined
|
| Dermal Toxicity: |
|
Not determined
|
| Inhalation Toxicity: |
inhalation-mouse LC > 7200000 mg/m3/4H BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: DYSPNEA Toksikologicheskii Vestnik. Vol. (3), Pg. 37, 1996.
inhalation-rat LC > 7200000 mg/m3/4H BEHAVIORAL: MUSCLE WEAKNESS
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
LUNGS, THORAX, OR RESPIRATION: DYSPNEA Toksikologicheskii Vestnik. Vol. (3), Pg. 37, 1996.
|
Safety in Use Information:
| Category: | | propellants, aerating agents, and gas |
| Recommendation for hydrofluorocarbon 227EA usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for hydrofluorocarbon 227EA flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | apaflurane | | | FM 200 | | 1,1,1,2,3,3,3- | heptafluoropropane | | 2H- | heptafluoropropane | | | HFA-227 | | | HFC 227 | | | HFC-227EA | | 2- | hydroheptafluoropropane | | 2- | hydroperfluoropropane | | | khladon 227 | | | propane, 1,1,1,2,3,3,3-heptafluoro-
| | | solkane 227 |
Articles:
| PubMed:Influence of Suspension Stabilisers on the Delivery of Protein-Loaded Porous Poly (DL-Lactide-co-Glycolide) (PLGA) Microparticles via Pressurised Metered Dose Inhaler (pMDI). |
| PubMed:Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. |
| PubMed:Solvent-solute interactions in hydrofluoroalkane propellants. |
| PubMed:Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. |
| PubMed:Characterization of fine particle and gaseous emissions during school bus idling. |
| PubMed:Determination of 1,1,1,2,3,3,3-heptafluoropropane (HFP) in blood by headspace gas chromatography-mass spectrometry. |
| PubMed:Influence of the size of micronized active pharmaceutical ingredient on the aerodynamic particle size and stability of a metered dose inhaler. |
| PubMed:Novel nanoparticles for pulmonary drug administration. |
| PubMed:Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3, 3-heptafluoropropane) following whole-body exposure. |
| PubMed:Setting safe acute exposure limits for halon replacement chemicals using physiologically based pharmacokinetic modeling. |
| PubMed:Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants. |
| PubMed:Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate. |
| PubMed:Biotransformation of the aerosol propellant 1,1,1,2,3,3,3-heptafluoropropane (HFA-227): lack of protein binding of the metabolite hexafluoroacetone. |
|